<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Financings</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Financings for April 30, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: AB Science, GH Research, Axoft, Hypervision Surgical, Intellia, Neurosense, Oruka, Tacalyx, Vivacta.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730756</guid>
      <pubDate>Thu, 30 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730756-financings-for-april-30-2026</link>
    </item>
    <item>
      <title>Tacalyx supports TCX-201 with seed extension financing</title>
      <description>
        <![CDATA[Tacalyx GmbH has selected its first clinical candidate, TCX-201, and secured €11 million (US$12.8 million) in a first closing of its seed extension round to support the program’s progression through preclinical development. TCX-201 is an antibody-drug conjugate (ADC) against an undisclosed tumor-associated carbohydrate antigen (TACA).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730791</guid>
      <pubDate>Thu, 30 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730791-tacalyx-supports-tcx-201-with-seed-extension-financing</link>
    </item>
    <item>
      <title>Financings for April 29, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Aventera, Climb, Coultreon, Fathom, Iantrek, Lighthouse, Mbiomics, Modus, Quest.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730690</guid>
      <pubDate>Wed, 29 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730690-financings-for-april-29-2026</link>
    </item>
    <item>
      <title>Enterobiotix raises $25.7M for phase IIb of microbiome pill in IBS</title>
      <description>
        <![CDATA[Microbiome specialist Enterobiotix Ltd. has raised £19 million (US$25.7 million) to fund phase IIb development of its lead program EBX-102-02 in the treatment of irritable bowel syndrome with constipation (IBS-C).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730688</guid>
      <pubDate>Wed, 29 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730688-enterobiotix-raises-257m-for-phase-iib-of-microbiome-pill-in-ibs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Glass-pound-symbol1.webp?t=1637697971" type="image/png" medium="image" fileSize="286512">
        <media:title type="plain">British pound symbol</media:title>
      </media:content>
    </item>
    <item>
      <title>CIRM grant to help advance Acurastem’s AS-241 toward clinic</title>
      <description>
        <![CDATA[Acurastem Inc. has been awarded $7.5 million in grant funding by the California Institute for Regenerative Medicine (CIRM) to support the advancement of lead clinical candidate AS-241 toward first-in-human testing.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730740</guid>
      <pubDate>Wed, 29 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730740-cirm-grant-to-help-advance-acurastems-as-241-toward-clinic</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-as-filament-in-light-bulb.webp?t=1695304772" type="image/jpeg" medium="image" fileSize="168302">
        <media:title type="plain">Brain as light bulb filament</media:title>
      </media:content>
    </item>
    <item>
      <title>Aventera raises funding for streptococcal infection program</title>
      <description>
        <![CDATA[Aventera Antibodies AB has successfully raised SEK14.5 million (US$15.6 million) in a funding round to support the preclinical development of the company’s lead drug candidate for life-threatening streptococcal infections.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730737</guid>
      <pubDate>Wed, 29 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730737-aventera-raises-funding-for-streptococcal-infection-program</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NIH-NIAID-Group-A-strep.webp?t=1750949355" type="image/png" medium="image" fileSize="1584691">
        <media:title type="plain">Microscopic image of Group A streptococcus bacteria.</media:title>
        <media:description type="plain">Group A Streptococcus bacteria. Credit: National Institute of Allergy and Infectious Diseases, NIH
</media:description>
      </media:content>
    </item>
    <item>
      <title>Ribo, Diagens tally 2 Hong Kong biotech, medtech IPOs in Q1 2026 </title>
      <description>
        <![CDATA[Ribo Life Science Co. Ltd.’s HK$1.8 billion (US$230 million) raise on Jan. 9 was the sole Chinese biotech IPO on the Hong Kong Stock Exchange in the first quarter (Q1) of 2026, despite a growing backlog of more than 70 filings from China life science firms in 2025. Among med-tech companies, Hangzhou Diagens Biotechnology Co. Ltd. debuted with a $101 million Hong Kong IPO March 30, 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730785</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730785-ribo-diagens-tally-2-hong-kong-biotech-medtech-ipos-in-q1-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Hong-Kong-HKEX.webp?t=1588782956" type="image/png" medium="image" fileSize="582891">
        <media:title type="plain">Hong Kong stock market illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Financings for April 28, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Citius, Fathom, Lucid, Plaquetec, Sagimet, Sanofi, Sonoma, Squaremind.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730676</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730676-financings-for-april-28-2026</link>
    </item>
    <item>
      <title>Nervonik raises $52.5M to advance PNS system</title>
      <description>
        <![CDATA[Nervonik Inc. raised $52.5 million in a series B financing round for its peripheral nerve stimulation (PNS) system designed to treat patients with chronic pain and other neurological conditions. The funds will be used to support the continued development Nervonik's PNS system, including enhancements to the system’s sensing capabilities, as well as preparations for commercialization.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730673</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730673-nervonik-raises-525m-to-advance-pns-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Gold-dollar-sign-and-blue-circular-arrows.webp?t=1729544931" type="image/jpeg" medium="image" fileSize="126086">
        <media:title type="plain">Gold dollar sign and blue circular arrows</media:title>
      </media:content>
    </item>
    <item>
      <title>CARB-X award supports Adjane’s gonorrhea vaccine</title>
      <description>
        <![CDATA[CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is awarding US$2.6 million to Adjane Holding BV to advance the development of a vaccine candidate to prevent infections caused by <em>Neisseria gonorrhoeae</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730720</guid>
      <pubDate>Tue, 28 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730720-carb-x-award-supports-adjanes-gonorrhea-vaccine</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Vaccine-research-vial-syringe.webp?t=1670859743" type="image/png" medium="image" fileSize="1080600">
        <media:title type="plain">Vaccine vial and syringe</media:title>
      </media:content>
    </item>
    <item>
      <title>Financing supports Fathom Therapeutics’ Microcosmos drug design engine</title>
      <description>
        <![CDATA[Fathom Therapeutics, formerly Atommap Corp., has raised $47 million in an oversubscribed series A financing to advance its work using physics-based simulations and AI to model protein motion and interactions at atomic resolution.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730719</guid>
      <pubDate>Tue, 28 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730719-financing-supports-fathom-therapeutics-microcosmos-drug-design-engine</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/finance-dollar-growth.webp?t=1638226495" type="image/png" medium="image" fileSize="416016">
        <media:title type="plain">Hand holding dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Financings for April 27, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Avalyn, Hemab, Nektar, Scinai, Seaport.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730660</guid>
      <pubDate>Mon, 27 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730660-financings-for-april-27-2026</link>
    </item>
    <item>
      <title>UK biotech funding in Q1 2026 hints a recovery is in the offing</title>
      <description>
        <![CDATA[The funding momentum that was building at the end of 2025 was maintained in the first quarter (Q1) of 2026, with a rebound in venture capital (VC) investment in U.K. biotech. Overall investment in the sector during Q1 was £552 million (US$748 million), of which £516 million was in VC.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730644</guid>
      <pubDate>Mon, 27 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730644-uk-biotech-funding-in-q1-2026-hints-a-recovery-is-in-the-offing</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Pill-with-British-pound-sign.webp?t=1627069868" type="image/png" medium="image" fileSize="33159">
        <media:title type="plain">Pill with British pound sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Financings for April 24, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Acuitymd, Altimmune, Ferrosa.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730623</guid>
      <pubDate>Fri, 24 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730623-financings-for-april-24-2026</link>
    </item>
    <item>
      <title>Ribo, Diagens tally 2 Hong Kong biotech, medtech IPOs in Q1 2026 </title>
      <description>
        <![CDATA[Ribo Life Science Co. Ltd.’s HK$1.8 billion (US$230 million) raise on Jan. 9 was the sole Chinese biotech IPO on the Hong Kong Stock Exchange in the first quarter (Q1) of 2026, despite a growing backlog of more than 70 filings from China life science firms in 2025. Among med-tech companies, Hangzhou Diagens Biotechnology Co. Ltd. debuted with a $101 million Hong Kong IPO March 30, 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730619</guid>
      <pubDate>Fri, 24 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730619-ribo-diagens-tally-2-hong-kong-biotech-medtech-ipos-in-q1-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Hong-Kong-HKEX.webp?t=1588782956" type="image/png" medium="image" fileSize="582891">
        <media:title type="plain">Hong Kong stock market illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Seed funding at Ferrosa Therapeutics</title>
      <description>
        <![CDATA[Ferrosa Therapeutics AG has announced a $3.5 million seed financing to support the development of a first-in-class bispecific antibody (FRS-101) to treat anemia of inflammation across chronic kidney disease, autoimmune disease and oncology indications.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730634</guid>
      <pubDate>Fri, 24 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730634-seed-funding-at-ferrosa-therapeutics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Seedling-coins.webp?t=1588792056" type="image/png" medium="image" fileSize="390216">
        <media:title type="plain">Coins and seedling</media:title>
      </media:content>
    </item>
    <item>
      <title>Financings for April 23, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Maze, Milestone, Nektar, Outlook, Preveceutical, Tarsier, Tuhura.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730608</guid>
      <pubDate>Thu, 23 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730608-financings-for-april-23-2026</link>
    </item>
    <item>
      <title>Financings for April 22, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Alesi Surgical, Deep Blue Medical, Flagship, Kailera, Pulmatrix, Ray, Serif, Spruce, Trevi.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730504</guid>
      <pubDate>Wed, 22 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730504-financings-for-april-22-2026</link>
    </item>
    <item>
      <title>Xuanzhu shares dip despite phase III ALK inhibitor data</title>
      <description>
        <![CDATA[Xuanzhu Biopharmaceutical Co. Ltd. reported positive data from a local phase III study of dirozalkib (Xuan Fei Ning), an ALK inhibitor approved in China to treat patients with advanced non-small-cell lung cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730579</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730579-xuanzhu-shares-dip-despite-phase-iii-alk-inhibitor-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Lung-cancer-illustration.webp?t=1621625770" type="image/png" medium="image" fileSize="543175">
        <media:title type="plain">Lung cancer illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Mabwell turns to Hong Kong to fund ADC ambitions</title>
      <description>
        <![CDATA[Following its 2022 debut on Shanghai’s STAR Market, Mabwell (Shanghai) Bioscience Co. Ltd. is aiming to raise up to HK$1.44 billion (US$184.78 million) in an IPO on the Hong Kong Stock Exchange to advance its Nectin4-targeting antibody-drug conjugate (ADC) 9MW-2821 (bulumtatug fuvedotin).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730578</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730578-mabwell-turns-to-hong-kong-to-fund-adc-ambitions</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/HKEX-exterior.webp?t=1632868875" type="image/png" medium="image" fileSize="621948">
        <media:title type="plain">HKEX exterior</media:title>
        <media:description type="plain">Credit: Lewis Tse Pui Lung - stock.adobe.com</media:description>
      </media:content>
    </item>
    <item>
      <title>Med-tech financings steady at $8.8B in Q1, despite volume drop</title>
      <description>
        <![CDATA[Total med-tech financings reached $8.81 billion in the first quarter (Q1) 2026, a 6% decline from $9.33 billion in Q1 2025 but well above the post-downturn lows of recent years. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730573</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730573-med-tech-financings-steady-at-88b-in-q1-despite-volume-drop</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Layered-charts.webp?t=1706913970" type="image/jpeg" medium="image" fileSize="137002">
        <media:title type="plain">Layered  charts </media:title>
      </media:content>
    </item>
    <item>
      <title>Financings for April 21, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Alamar, Amanat, Marvel, Mobia, Modular, Odyssey, Prelude, Revolution, Screenpoint, Sharp.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730490</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730490-financings-for-april-21-2026</link>
    </item>
    <item>
      <title>Tortugas launches with $106M for neurology, neuropsychiatric drugs</title>
      <description>
        <![CDATA[Tortugas Neuroscience Inc. came out of its shell to announce the raising of $106 million between its seed and series A financing rounds. “We like the symbolism of the sea turtle – long-lived, persistent, very determined,” Tortugas CEO Jeff Jonas said of the company’s name.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730482</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730482-tortugas-launches-with-106m-for-neurology-neuropsychiatric-drugs</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Jeff-Jonas-CEO-and-Al-Robichaud-president-head-of-RD-Tortugas-4-21.webp?t=1776806199" type="image/jpeg" medium="image" fileSize="420579">
        <media:title type="plain">Jeff Jonas, CEO and Al Robichaud, president, head of R&amp;D, Tortugas Neuroscience</media:title>
        <media:description type="plain">Tortugas Neuroscience Inc. is led by Jeff Jonas, CEO (left), 
and Al Robichaud, president and head of R&amp;amp;D.
</media:description>
      </media:content>
    </item>
    <item>
      <title>Financings for April 21, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies in Asia-Pacific raising money in public or private financings: Senhwa, Telix.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730531</guid>
      <pubDate>Tue, 21 Apr 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730531-financings-for-april-21-2026</link>
    </item>
    <item>
      <title>Financings for April 20, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Allogene, Alloy, Enveric, JATT II, Orthogon, Spyre, Trevi, Ultralight, Vaxart.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730476</guid>
      <pubDate>Mon, 20 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730476-financings-for-april-20-2026</link>
    </item>
    <item>
      <title>Medtronic leads $100M financing round for Pulnovo</title>
      <description>
        <![CDATA[Pulnovo Medical Ltd. secured $100 million in a financing round led by Medtronic plc for its pulmonary artery denervation system to treat pulmonary hypertension. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730471</guid>
      <pubDate>Mon, 20 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730471-medtronic-leads-100m-financing-round-for-pulnovo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Money-financing.webp?t=1588371985" type="image/png" medium="image" fileSize="253228">
        <media:title type="plain">Hand holding gear, dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Xuanzhu shares dip despite phase III ALK inhibitor data</title>
      <description>
        <![CDATA[Xuanzhu Biopharmaceutical Co. Ltd. reported positive data from a local phase III study of dirozalkib (Xuan Fei Ning), an ALK inhibitor approved in China to treat patients with advanced non-small-cell lung cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730470</guid>
      <pubDate>Mon, 20 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730470-xuanzhu-shares-dip-despite-phase-iii-alk-inhibitor-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Lung-cancer-illustration.webp?t=1621625770" type="image/png" medium="image" fileSize="543175">
        <media:title type="plain">Lung cancer illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Mabwell turns to Hong Kong to fund ADC ambitions</title>
      <description>
        <![CDATA[Following its 2022 debut on Shanghai’s STAR Market, Mabwell (Shanghai) Bioscience Co. Ltd. is aiming to raise up to HK$1.44 billion (US$184.78 million) in an IPO on the Hong Kong Stock Exchange to advance its Nectin4-targeting antibody-drug conjugate (ADC) 9MW-2821 (bulumtatug fuvedotin).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730409</guid>
      <pubDate>Mon, 20 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730409-mabwell-turns-to-hong-kong-to-fund-adc-ambitions</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/HKEX-exterior.webp?t=1632868875" type="image/png" medium="image" fileSize="621948">
        <media:title type="plain">HKEX exterior</media:title>
        <media:description type="plain">Credit: Lewis Tse Pui Lung - stock.adobe.com</media:description>
      </media:content>
    </item>
    <item>
      <title>Orthogon Therapeutics raises funds to advance anti-BK virus drug</title>
      <description>
        <![CDATA[Orthogon Therapeutics LLC has closed an $11 million follow-on financing, bringing its total capital raised to $36 million. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730514</guid>
      <pubDate>Mon, 20 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730514-orthogon-therapeutics-raises-funds-to-advance-anti-bk-virus-drug</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/RD-money.webp?t=1588877677" type="image/png" medium="image" fileSize="578436">
        <media:title type="plain">Dollar sign droplet above test tube</media:title>
      </media:content>
    </item>
    <item>
      <title>Financings for April 17, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Achieve Life Sciences, Acurx, Adlai, Meiragtx, Onward, Pamdx.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730412</guid>
      <pubDate>Fri, 17 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730412-financings-for-april-17-2026</link>
    </item>
  </channel>
</rss>
